Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$79.15 USD

79.15
577,606

-2.66 (-3.25%)

Updated Aug 5, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected

IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.

    Arpita Dutt headshot

    Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops

    Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.

      5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

      Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

        Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

        We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

          Swarup Gupta headshot

          Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz

          The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting.

            AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval

            AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.

              Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance

              Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.

                Arpita Dutt headshot

                Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?

                Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.

                  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA

                  AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation

                    Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula

                    TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.

                      AstraZeneca's Lung Cancer Drug Tagrisso Approved in China

                      AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.

                        AstraZeneca Stock Rising in '17: What's Working in its Favor?

                        Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.

                          Infinity Pharma Focuses on Cancer Drug: Competition Looms

                          We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

                            AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

                            London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

                              AstraZeneca (AZN): Should Value Investors Pick this Stock?

                              Is AstraZeneca a great pick from the value investor's perspective right now? Read on to know more.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

                                Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

                                  Inovio (INO) Q4 Loss Wider than Expected; Shares Decline

                                  Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.

                                    AstraZeneca's Cancer Drug Lynparza Positive in Phase III

                                    AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.

                                      Arpita Dutt headshot

                                      How Incyte Stock Became a Bull Market Star for Biotech Investors

                                      Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

                                        Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

                                        Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

                                          The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

                                          The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug

                                            Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.

                                              Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                                              Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                                                Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

                                                Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

                                                  Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.